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Ross J. Baldessarini, M.D.
Objective: Patterns of clinical use of antipsychotic agents have
changed greatly in the past decade. The authors’ goal was to ex-
amine these patterns.
Method: They evaluated medication use in all McLean Hospi-
tal inpatients treated with antipsychotic drugs during 3 months
in 1998 (N=349) and compared the results with McLean Hospi-
tal inpatients treated with antipsychotics in 1993 (N=299) and
Boston area inpatients in 1989 (N=50).
Results: The most commonly prescribed antipsychotics in
1998 were atypical agents; olanzapine was prescribed more of-
ten than risperidone or quetiapine, which were prescribed
more often than other antipsychotics. Two or more antipsychot-
ics were prescribed at some time during their hospitalization
for 150 (43%) of the patients in 1998. The total discharge dose
in chlorpromazine equivalents for the 349 patients for whom
antipsychotics were prescribed at discharge was 371 mg/day,
29% higher than the total discharge dose for patients in 1993
and 46% greater than the dose in 1989. The dose of antipsy-
chotics was greater for patients with psychotic illnesses than for
those with affective illnesses. Higher doses were associated with
greater clinical improvement, polypharmacotherapy, and
younger patient age.
Conclusions: Emerging trends toward higher total antipsy-
chotic doses and polypharmacotherapy require critical assess-
ments of cost-benefit relationships.
(Am J Psychiatry 2002; 159:1932–1935)
We surveyed hospital practices in the Boston area re-
garding use of antipsychotic drugs in 1984, 1989, and 1993
(1, 2). In contrast to earlier American practices, mean
chlorpromazine-equivalent daily doses fell by the late
1980s, to accord with standard international practices,
and conservative dosing was sustained into the early
1990s (2, 3). More recently, growing numbers of atypical
antipsychotics have entered clinical use, along with other
innovative treatments (4). It is our clinical impression,
supported by recent research reports (5–8), that simulta-
neous use of multiple dissimilar antipsychotics is increas-
ing. Accordingly, we completed a new survey of antipsy-
chotic use to document current trends compared with our
earlier findings over the past decade (1, 2).
Method
Consecutive patients admitted to McLean Hospital in March–
May 1998 who were treated with antipsychotic medications were
considered. Following review and approval for confidential and
anonymous use of aggregate data by the hospital’s institutional
review board, we reviewed clinical records to determine the pa-
tient’s sex, age, discharge DSM-IV diagnosis, and all medications
given, with their doses and times.
Doses of antipsychotics were converted to chlorpromazine
equivalents (mg/day) on the basis of potency ratios of approxi-
mate median recommended daily doses to chlorpromazine at 400
mg/day (4) (Table 1). For each patient, we compiled initial, maxi-
mum, and final (discharge) doses of primary antipsychotic agents
(those used for the majority of inpatient days), as well as the total
final dose when multiple antipsychotics were given. Comparisons
were made of McLean patients treated in 1998 (N=349) with simi-
lar McLean inpatients in 1993 (N=299) and Boston area patients
in 1989 (N=50) (2). Data on patients’ clinical improvement were
obtained from hospital discharge records.
Averages are means and standard deviations. Continuous data
were compared by using one-way analysis of variance, paired t
tests, or unpaired t tests for unequal groups across years. Categor-
ical data were compared by using contingency tables (chi-
square). Correlations were based on Spearman nonparametric
rank methods (rs). Factors associated with median-split final total
chlorpromazine-equivalent dose were evaluated by logistic re-
gression multivariate methods (risk ratio and 95% confidence in-
terval [CI]). We used Statview-5 programs (SAS Corp., Cary, N.C.)
for statistical analyses.
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Results
In the 3-month 1998 group, antipsychotics were pre-
scribed for 377 (50%) of 754 psychiatric inpatients; antipsy-
chotics were prescribed for 349 of these patients at the time
of their hospital discharge. These 349 inpatients comprise
the present study group of 211 women (60.0%) and 138
men (40.0%). The patients’ mean age was 45.7 years (SD=
19.6, range=18–91), and they were hospitalized for a mean
of 29.0 days (SD=26.2) (compared with a mean of 18.5 days
in 1993 and 73.1 days in 1989). Their DSM-IV diagnoses
were primary psychosis (N=136 [39.0%]), major depression
(N=73 [20.9%]), bipolar disorder (N=78 [22.3%]), dementia
(N=41 [11.7%]), substance use (N=8 [2.3%]), and miscella-
neous disorders (N=13 [3.7%]). Average time from admis-
sion to first antipsychotic dose was 0.9 days (versus 1.5 in
1993 and 6.8 in 1989).
The ranking of antipsychotic use for the 349 patients
was as follows: olanzapine 36%, risperidone 17%, quetia-
pine 17%, perphenazine 10%, clozapine 6%, and haloperi-
dol for 6%; other typical neuroleptics were used for 3% or
less of the patients (Table 1). An atypical agent was the ini-
tial treatment for 254 (72.8%) of the patients; women
started with atypical agents nonsignificantly more often
than men (N=107 [77.5%] compared with N=145 [69.7%])
(χ2=2.61, df=1, p=0.11). Frequency of atypical primary
agents among all antipsychotics was similar across diag-
nostic groups: psychotic (N=101 [74.3%]), affective (N=108
[71.5%]), and other disorders (N=50 [80.6%]).
Atypical agents were used in lower initial chlorprom-
azine-equivalent doses than typical neuroleptics (mean=
190 mg/day, SD=164, versus mean=318 mg/day, SD=384)
(F=20.5, df=1, 375, p<0.0001) as well as in lower discharge
doses (mean=277 mg/day, SD=202, versus mean=438 mg/
day, SD=415) (F=22.9, df=1, 347, p<0.0001). Maximum and
total final doses of chlorpromazine and thioridazine were
the most conservative, and the doses of fluphenazine, lox-
apine, and thiothixene were the highest (Table 1).
At discharge, two or more antipsychotics were prescribed
for 55 [15.8%] of the patients (37 [17.5%] of the women and
18 [13.0%] of the men). By diagnosis, discharge polyphar-
macotherapy ranked as follows: psychotic (N=34 [25.0%]),
affective (N=16 [10.6%]), and other (N=5 [8.1%]) disorders
(χ2=14.5, df=2, p=0.0007). However, this practice included
133 (38.1%) of patients at some time during hospitalization
and accounted for 20.0% of inpatient days in 1998, com-
pared with 5.7% of inpatient days in 1993 and 1.7% in 1989
(1, 2). Typical neuroleptics were added only to primary
atypical antipsychotics, but atypical agents were com-
bined with both typical (217 patients [62.2%]) and other
atypical (132 patients [37.8%]) primary antipsychotics.
The chlorpromazine-equivalent mean dose at discharge
was 317 mg/day (SD=279) for primary agents but 371 mg/
day (SD=348) with combinations included (Table 1) (t=
5.92, df=348, p<0.0001). Discharge doses were also higher
than initial doses (t=18.3, df=348, p<0.0001) but not signifi-
cantly different from final doses in 1993 (t=1.85, df=646, p=
0.08), although 24.8% greater than in 1989 (t=6.03, df=387,
p<0.0001) (Table 1). However, the final total dose in 1998
was 29.3% greater than in 1993 (t=3.48, df=646, p<0.001)
and 46.1% greater than in 1989 (t=2.56, df=397, p<0.02).
Discharge total doses were also 24.9% greater in men
than women (mean=422 mg/day, SD=379, versus mean=
TABLE 1. Daily Dose of Antipsychotic Agents During Hospitalization at McLean Hospital Among All Inpatients Treated With





Dose (mg/day of chlorpromazine equivalents)b
Initial Maximum
Finalc
Primary Antipsychotic All Antipsychotics
N % Mean SD Mean SD Mean SD Mean SD
Inpatients treated
for 3 months in 1998
Olanzapine 125 35.8 25.0 229 151 321 180 302 186 376 342
Risperidone 59 16.9 80.0 182 173 267 226 242 221 265 249
Quetiapine 58 16.6 0.5 122 133 266 188 219 157 296 228
Perphenazine 34 9.7 14.0 330 294 443 342 422 354 428 349
Clozapine 21 6.0 1.5 220 252 442 275 388 282 429 336
Haloperidol 21 6.0 50.0 280 191 411 244 379 252 422 473
Thioridazine 12 3.4 1.0 117 83 172 103 165 107 165 107
Fluphenazine 9 2.6 40.0 920 739 1,093 627 951 677 1,066 687
Chlorpromazine 5 1.4 1.0 105 110 250 71 175 117 195 148
Thiothixene 3 0.9 25.0 579 469 1,068 935 757 505 924 714
Loxapine 2 0.6 12.0 865 752 931 658 831 799 1,098 422
Total 349 100.0 235 256 351 294 317 279 371 348
Inpatients treated with 
antipsychotics in 1993 299 100.0 283 333 367 345 287 302 — —
Inpatients treated with 
antipsychotics in 1989 50 100.0 238 270 269 321 254 233 — —
a Twenty-eight of the 377 patients who were given antipsychotic medication during their hospitalization were discharged without antipsy-
chotic medication and are not included in this table.
b Based on multiples of the proposed potency ratios (approximate median recommended daily doses to chlorpromazine at 400 mg/day).
c The final dose of the primary antipsychotic (used for a majority of days) was at hospital discharge; the final total dose includes all antipsy-
chotics used at discharge.
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338 mg/day, SD=323) (F=4.90, df=1, 347, p=0.03). However,
65 (47.1%) of the men were psychotic, whereas 101 (47.9%)
of the women were affectively ill (χ2=6.64, df=1, p=0.04).
By diagnosis, final total doses were ranked as follows:
primary psychosis (mean=547 mg/day, SD=418), major af-
fective disorder (mean=286 mg/day, SD=240), and other
disorders (mean=194 mg/day, SD=209) (overall F=35.8,
df=2, 346, p<0.0001). The final total dose fell somewhat
with increasing age (rs=–0.22, N=349, p<0.001) and was
higher in patients with ratings of moderate or major than
in those with ratings of minor or no improvement (mean=
423 mg/kg, SD=397, versus mean=329 mg/kg, SD=371) (F=
2.95, df=1, 193, p=0.09) but was unrelated to longer hospi-
talization (rs=–0.08, N=349, p<0.14).
Since some factors may covary, multivariate analysis
was applied. Four factors were associated with higher to-
tal discharge chlorpromazine-equivalent antipsychotic
dose: psychotic versus major affective diagnosis (risk ra-
tio=6.80, 95% CI=3.22–14.3), greater clinical improvement
(risk ratio=3.36, 95% CI=1.65–6.84), use of two or more
antipsychotics (risk ratio=1.94, 95% CI=1.14–3.22), and
younger age (risk ratio=1.03, 95% CI=1.01–1.05). Dis-
charge dose was no longer associated with sex, number of
days in the hospital, primary agent typical versus atypi-
cal, use of depot neuroleptic, or use of a supplemental
sedative.
Discussion
Over the past decade, atypical agents have emerged as
the dominant choice among antipsychotics. At our hospi-
tal in 1993 (2), atypical agents accounted for only 12% of
antipsychotics prescribed, compared with 72% in 1998
(Table 1). The most commonly used agents in 1998 were
olanzapine, risperidone, and quetiapine (olanzapine was
used more than risperidone, which was used as much as
quetiapine), and atypical agents were used at similar rates
across diagnostic groups. By multivariate analysis, total
chlorpromazine-equivalent discharge doses were sig-
nificantly higher for patients with psychotic diagnoses
than those with major affective diagnoses, for those with
greater clinical improvement during hospitalization (de-
spite clinically individualized dosing), those prescribed
multiple antipsychotics, and younger patients. Discharge
doses were not significantly related to sex, hospital stay,
typical/atypical antipsychotic type, or addition of seda-
tives. Total discharge chlorpromazine-equivalent anti-
psychotic doses increased by approximately 46% over the
past decade.
It seems unlikely that increasing total doses of antipsy-
chotics reflect major changes in admission policies or the
impact of managed care. The length of stay did not de-
crease between 1993 and 1998 (range=19–29 days). In-
stead, increasing antipsychotic dosing appears to reflect
use of moderate doses of individual agents but a rising cu-
mulative total because of polypharmacotherapy. Simulta-
neous use of two or more antipsychotics was found in 55
(15.8%) of the patients in the 1998 study group at dis-
charge, but in 133 (38.1%) at some time during hospital-
ization. The most frequent combinations involved typical
antipsychotics added to atypical primary agents. This ten-
dency may reflect incomplete confidence in monotherapy
with atypical antipsychotic agents in inpatient practice.
Additional combinations of several psychotropic agents
also were common in 1998 (69 [19.8%] of the patients re-
ceived four or more agents).
Polypharmacotherapy in major psychiatric disorders is
a growing international phenomenon, despite lack of re-
search evidence of superior effectiveness without com-
promising safety or acceptable financial cost (5–12). We
conclude that upward trends in total antipsychotic dosing
and growing use of different forms of polypharmacother-
apy require additional empirical study with modern anti-
psychotic agents to evaluate critically their risks, benefits,
and costs.
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Brief Report
Psychopharmacologic Treatment of Generalized Anxiety 
Disorder and the Risk of Major Depression
Renée D. Goodwin, Ph.D.
Jack M. Gorman, M.D.
Objective: The authors sought to determine the association
between treatment for generalized anxiety disorder and the
risk of major depression among adults in the community.
Method: Data were drawn from the National Comorbidity
Survey (N=8,098), a representative sample of the United States
population age 15–54. Cox proportional hazards were used to
determine the association between specific forms of treat-
ment for generalized anxiety disorder and the risk of major
depression.
Results: Psychopharmacologic treatment of generalized anxi-
ety disorder was associated with a significantly lower risk of ma-
jor depression. There was no significant association between ei-
ther having seen a mental health professional for generalized
anxiety disorder or having been prescribed a medication for
generalized anxiety disorder and the risk of depression.
Conclusions: These results suggest an association between
treatment for generalized anxiety disorder and lower risk of de-
pression, which appears specific to pharmacologic treatment.
Future research that leads to a more precise delineation of the
underlying mechanism of the observed association is needed to
identify and develop effective strategies to prevent onset of
depression.
(Am J Psychiatry 2002; 159:1935–1937)
The majority of data from epidemiology and clinical
studies suggest that generalized anxiety disorder and ma-
jor depression co-occur more frequently than would be
expected by chance (1–3). The co-occurrence of these two
disorders is associated with significantly greater psychiat-
ric comorbidity, social and occupational impairment, and
suicidal ideation and suicide behavior compared with ei-
ther disorder without the other (4–7). Previous evidence
suggests that the onset of generalized anxiety disorder oc-
curs before the onset of major depression in the majority
of cases (8–10) and that in some cases, generalized anxiety
disorder may be a precursor to the onset of major depres-
sion (1, 2, 4–6, 8).
Despite the well-documented finding that most people
with one mental disorder will develop at least one other
disorder in their lifetime, there remain relatively few data
on the feasibility of the prevention of secondary comor-
bidity and even less that describe effects associated with
specific types of treatment. The goal of the current study
was to determine the association between the treatment
of generalized anxiety disorder and the risk of depression
among adults in the community.
Method
The National Comorbidity Survey is based on a national proba-
bility sample of individuals 15–54 years of age in the noninstitu-
tionalized population (11). Fieldwork was carried out between
September 1990 and February 1992. There was an 82.4% response
rate. The total sample includes 8,098 interviewed respondents. The
data were weighted for differential probabilities of selection and
nonresponse. Weights are described in detail elsewhere (11, 12).
The group under study consisted of respondents with diag-
noses of generalized anxiety disorder (lifetime prevalence) (N=
219), either with depression (with onset occurring after onset of
generalized anxiety disorder) or without depression. Diagnoses
were generated from a modified version of the World Health Or-
ganization (WHO) Composite International Diagnostic Interview,
a structured interview designed for use by lay interviewers (13).
WHO field trials and National Comorbidity Survey clinical reap-
praisal studies have documented acceptable reliability and valid-
ity for these diagnoses (13–15).
For the diagnostic sections that assessed symptoms of gener-
alized anxiety disorder, respondents were asked whether they
had ever seen a mental health specialist (defined as a psychia-
trist, psychologist, or social worker) regarding these symptoms,
been prescribed a medication for treatment of the symptoms,
and whether they had taken medication for the symptoms at
least four times or more. Psychopharmacologic treatment was
defined as respondents who endorsed having taken psychotro-
